DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the BLISS GVS PHARMA LTD (BLISSGVS) share price today?

BLISS GVS PHARMA LTD (BLISSGVS) is trading at ₹483.5 on the NSE, down 4.25% on the day. Source: DocStoX.

What is the PE ratio of BLISS GVS PHARMA LTD?

BLISS GVS PHARMA LTD has a price-to-earnings (PE) ratio of 39.6 in the Healthcare sector.

What is the market capitalisation of BLISS GVS PHARMA LTD?

BLISS GVS PHARMA LTD has a market capitalisation of approximately ₹5,120 crore.

BLISS GVS PHARMA LTD

BLISSGVS·NSE·Healthcare

₹483.50▼ -21.45 (-4.25%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹479.75

₹510.00

52W₹118

₹55384%

Open

₹505.20

High

₹510.00

Low

₹479.75

Prev Close

₹504.95

Volume

3.67L

VWAP

₹486.71

Snapshot

Key fundamentals

Market Cap

₹5,120 Cr

P/E Ratio

39.60Expensive

P/B Ratio

4.66

EPS

₹12.21

Book Value

₹113.00

ROE

11.80%Average

ROCE

17.00%Decent

Dividend Yield

0.29%

Debt / Equity

0.02Low

Face Value

₹1.00

52W High

₹553.00

52W Low

₹118.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹127

▼ 73.8%downside

Trading at ₹484 — 74% above our estimate

BearFair valueBull

₹108₹127₹176

/100

Business quality — Watch the fundamentals

Growth 56Profitability 52Efficiency 23Valuation 63

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 1/9)

Strengths

Virtually debt-free balance sheet
Profit growing 21% a year

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

12% ROE fading to 12% over ~3 yrs, on ₹113 book

₹113

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹176

Analyst target

No analyst coverage

—

Blended fair value₹127

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Profit growing 21% a year

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

39.6Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

11.8%Average

Above 15% is considered healthy for Indian equities

ROCE

17.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.02Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹5,120 Cr

P/B

4.66

EPS

₹12.21

Div Yield

0.29%

What changed

Recent changes

Foreign investors-4.1% stake last quarter
Domestic institutions-0.7% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 39.6×

Growth

Steady

+7% rev CAGR

Profitability

Modest

11.8% ROE

Financial health

Rock solid

D/E 0.02

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹1787.36L Cr

Trades4,190

VWAP₹486.71

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+7.2%

+9.9%

10Y

+5.4%

Profit

+20.6%

+12.8%

10Y

+3.0%

EPS

+21.5%

+13.0%

10Y

+4.3%

Profile

Pros

Company has reduced debt.
Company is almost debt free.

Watch-outs

Cons

Stock is trading at 4.65 times its book value
The company has delivered a poor sales growth of 9.94% over past five years.
Company has a low return on equity of 10.2% over last 3 years.
Earnings include an other income of Rs.67.5 Cr.
Company has high debtors of 204 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 4.09 pts; domestic institutions reduced 0.74 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

35%

Promoter

Promoters

35.4%0.00

Public

49.1%+4.83

FII / FPI

10.4%-4.09

DII

5.0%-0.74

Total shareholders

44,874+1,494 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter35.36%

FII10.45%

DII5.04%

Public49.15%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions